Cardinal Health, Inc.

CAH

US14149Y1082

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-24 pm EDT			5-day change	1st Jan Change
103.5 ^USD	+0.16%		-2.80%	+2.72%

Apr. 24	Evercore ISI Adjusts Cardinal Health's Price Target to $110 From $118, Keeps In Line Rating	MT
Apr. 23	Morgan Stanley Adjusts Cardinal Health's Price Target to $114 From $117, Maintains Overweight Rating	MT

Cardinal Health, Inc.(NYSE:CAH) added to Russell Midcap Value Index

June 25, 2021 at 12:00 am EDT

Latest news about Cardinal Health, Inc.

Evercore ISI Adjusts Cardinal Health's Price Target to $110 From $118, Keeps In Line Rating	Apr. 24	MT
Morgan Stanley Adjusts Cardinal Health's Price Target to $114 From $117, Maintains Overweight Rating	Apr. 23	MT
Sector Update: Health Care Stocks Increase Late Afternoon	Apr. 22	MT
Wall St stocks advance with major corporate earnings in view after market rout	Apr. 22	RE
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Apr. 22	MT
Sector Update: Health Care	Apr. 22	MT
US Equity Indexes Rise Before Busy Week of Earnings; Gold Slumps as Middle East Concerns Ease	Apr. 22	MT
US Equity Indexes Rise, Gold Slumps at Midday	Apr. 22	MT
Stocks in motion: Microstrategy, Verizon, Cardinal Health...	Apr. 22
Leerink Partners Adjusts Price Target on Cardinal Health to $118 From $125	Apr. 22	MT
Cardinal Health Not Renewing Distribution Contracts With OptumRx; Reaffirms Fiscal 2024 Non-GAAP EPS Outlook	Apr. 22	MT
Cardinal Health says contracts with UnitedHealth's OptumRx will not be renewed	Apr. 22	RE
Cardinal Health will not renew contracts with OptumRx	Apr. 22	RE
AdaptHealth Names Suzanne Foster CEO	Apr. 17	DJ
Cardinal Health Announces Location of Pharmaceutical Distribution Center for Over-The-Counter Products	Apr. 02	CI
Cardinal Health Gains Approval for Science-Based Targets to Cut Greenhouse Gas Emissions	Mar. 15	MT
Transcript : Cardinal Health, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM	Mar. 13
Cardinal Health, Inc. Elects Robert "Bob" Azelby as Independent Director, Effective March 1, 2024	Feb. 28	CI
Leerink Partners Starts Cardinal Health With Outperform Rating, $125 Price Target	Feb. 26	MT
US FTC, DHHS Request Information on Shortages of Generic Drugs; McKesson Shares Ease	Feb. 14	MT
Binx health, inc. Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-Waived, FDA-Cleared binx io	Feb. 12	CI
North American Morning Briefing : Stock Futures -2-	Feb. 12	DJ
Argus Upgrades Cardinal Health to Buy From Hold, Price Target is $120	Feb. 09	MT
Cardinal Health Keeps Quarterly Dividend at $0.5006 a Share, Payable April 15 to Shareholders of Record April 1	Feb. 06	MT
Cardinal Health Approves Quarterly Dividend, Payable on April 15, 2024	Feb. 06	CI

Cardinal Health, Inc. is specialized in the distribution of products and health services to pharmacies, hospitals and medical practices. Net sales break down by activity as follows: - distribution of pharmaceutical products (92.7%); - distribution of medical, surgical and laboratory products (7.3%). The group also develops a manufacturing of medical and surgical products activity (masks, overalls, gloves, diagnostic products, products of aspiration and collection of liquids, radiology intervention, respiratory assistance, etc.). The United States accounts for 97.7% of net sales.

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q3 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Cardinal Health, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

103.5 USD

Average target price

112.9 USD

Spread / Average Target

+9.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
CARDINAL HEALTH, INC.	+2.72%	25.14B
MCKESSON CORPORATION	+15.65%	69.91B
SINOPHARM GROUP CO. LTD.	+4.89%	8.32B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.10%	8.07B
HUADONG MEDICINE CO., LTD	-21.85%	7.97B
H. LUNDBECK A/S	+0.73%	4.56B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+17.40%	4.31B
EBOS GROUP LIMITED	-0.14%	3.99B
GALENICA AG	-2.34%	3.87B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+21.03%	3.63B

Pharmaceuticals Wholesale